Uncover Expert Analysis Before Investing in DGX

By Susan Ramirez • Thursday, March 20 15:09 • Permanent Link

Quest Diagnostics logged a -1.0% change during today's afternoon session, and is now trading at a price of $166.27 per share. The S&P 500 index moved -0.0%. DGX's trading volume is 506,643 compared to the stock's average volume of 1,056,570.

Quest Diagnostics trades -6.11% away from its average analyst target price of $177.09 per share. The 16 analysts following the stock have set target prices ranging from $159.0 to $191.0, and on average have given Quest Diagnostics a rating of buy.

If you are considering an investment in DGX, you'll want to know the following:

Quest Diagnostics's current price is 71.4% above its Graham number of $96.98, which implies that at its current valuation it does not offer a margin of safety
Quest Diagnostics has moved 30.4% over the last year, and the S&P 500 logged a change of 8.3%
Based on its trailing earnings per share of 7.69, Quest Diagnostics has a trailing 12 month Price to Earnings (P/E) ratio of 21.6 while the S&P 500 average is 29.3
DGX has a forward P/E ratio of 17.0 based on its forward 12 month price to earnings (EPS) of $9.76 per share
Its Price to Book (P/B) ratio is 2.72 compared to its sector average of 3.53
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
Based in Secaucus, the company has 45,000 full time employees and a market cap of $18.45 Billion. Quest Diagnostics currently returns an annual dividend yield of 1.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.